Mercury Biopharmaceutical Corporation (6932.TWO)
TWD 13.3
(-2.56%)
TWD 13.3
(-2.56%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 1.03 Million | 2.68 Million | - | - | - |
| Cost of Revenue | 441 Thousand | 1.5 Million | - | - | - |
| Gross Profit | 592 Thousand | 1.17 Million | - | - | - |
| Operating Expenses | 592 Thousand | 32.07 Million | 5.29 Million | 210 Thousand | - |
| Selling, General and Administrative Expenses | 24.91 Million | 16.66 Million | 2.48 Million | 210 Thousand | - |
| Research and Development Expenses | 21.36 Million | 15.41 Million | 2.81 Million | - | - |
| Other Expenses | - | -280 Thousand | - | - | - |
| Cost and Expenses | 46.72 Million | 33.57 Million | 5.29 Million | 210 Thousand | - |
| Operating Income | -45.69 Million | -30.85 Million | -5.29 Million | -210 Thousand | - |
| Interest Expense | 711 Thousand | 400 Thousand | 11 Thousand | - | - |
| Income Tax Expense | - | - | - | -210 Thousand | - |
| Earnings before Tax | -43.81 Million | -31.25 Million | -5.3 Million | -210 Thousand | - |
| Net Income | -43.81 Million | -31.25 Million | -5.3 Million | -210 Thousand | - |
| Earnings Per Share Basic | -0.11 | -0.08 | -0.02 | -0.00 | -0.00 |
| Earnings Per Share Diluted | -0.11 | -0.08 | -0.02 | -0.00 | -0.00 |
| Weighted Average Shares Outstanding | 410.27 Million | 378.73 Million | 278.3 Million | 104.64 Million | 351.28 Million |
| Weighted Average Shares Outstanding (Diluted) | 398.32 Million | 378.73 Million | 278.3 Million | 104.64 Million | 351.28 Million |
| Gross Margin | 0.57 | 0.44 | - | - | - |
| EBIT Margin | -37.79 | -10.49 | - | - | - |
| Profit Margin | -42.42 | -11.66 | - | - | - |
| EBITDA | -39.03 Million | -28.1 Million | -4.32 Million | -210 Thousand | - |
| Earnings Before Tax Margin | -44.23 | -11.51 | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 2.35 Million | 2.35 Million | 516.49 Thousand | 1.03 Million | 516.49 Thousand | - |
| Cost of Revenue | 370.5 Thousand | 370.5 Thousand | 220.5 Thousand | 441 Thousand | 220.5 Thousand | - |
| Gross Profit | 1.98 Million | 1.98 Million | 295.99 Thousand | 592 Thousand | 295.99 Thousand | - |
| Operating Expenses | 12.18 Million | 12.09 Million | 13.76 Million | 46.28 Million | 13.76 Million | 9.62 Million |
| Selling, General and Administrative Expenses | 6.08 Million | 6.08 Million | 7.31 Million | - | 7.31 Million | 5.14 Million |
| Research and Development Expenses | 6.1 Million | 6.1 Million | 6.18 Million | - | 6.18 Million | 4.49 Million |
| Other Expenses | - | - | - | -483 Thousand | - | - |
| Cost and Expenses | 12.55 Million | 12.46 Million | 13.98 Million | 46.72 Million | 13.98 Million | 9.62 Million |
| Operating Income | -10.19 Million | -10.19 Million | -13.2 Million | -43.1 Million | -13.2 Million | -9.64 Million |
| Interest Expense | - | - | - | 711 Thousand | - | - |
| Income Tax Expense | 12.5 Thousand | 12.5 Thousand | - | - | - | - |
| Earnings before Tax | -9.13 Million | -9.13 Million | -12.55 Million | -43.81 Million | -12.55 Million | -9.35 Million |
| Net Income | -9.15 Million | -9.15 Million | -12.55 Million | -43.81 Million | -12.55 Million | -9.35 Million |
| Earnings Per Share Basic | -0.02 | -0.02 | -0.03 | - | -0.03 | -0.02 |
| Earnings Per Share Diluted | -0.02 | -0.02 | -0.03 | - | -0.03 | -0.02 |
| Weighted Average Shares Outstanding | 415.72 Million | 457.55 Million | 416.06 Million | 410.27 Million | 416.06 Million | 404.5 Million |
| Weighted Average Shares Outstanding (Diluted) | 415.72 Million | 457.55 Million | 416.05 Million | 398.32 Million | 416.05 Million | 404.49 Million |
| Gross Margin | 0.84 | 0.84 | 0.57 | 0.57 | 0.57 | - |
| EBIT Margin | -3.76 | -3.64 | -23.80 | - | -23.80 | - |
| Profit Margin | -3.88 | -3.88 | -24.31 | -42.42 | -24.31 | - |
| EBITDA | -8.85 Million | -8.58 Million | -12.29 Million | - | -12.29 Million | -9.05 Million |
| Earnings Before Tax Margin | -4.32 | -4.32 | -25.56 | -41.73 | -25.56 | - |
OPGN
603429
MICRD
8272
VIVIDM
CRAFTSMAN